Breast Cancer Treatment and the Heart: Protecting Both

For a woman facing breast cancer, the heart is understandably not the first concern. As survival rates improve, and they have improved substantially over the past three decades, the cardiac consequences of treatment have moved from an afterthought to a defined subspecialty with its own guidelines, monitoring protocols, and preventive interventions. Some of the treatments that save lives can also affect the heart in ways that are now predictable enough to anticipate, monitor, and in many cases prevent or substantially limit. That is the premise of cardio-oncology: effective cancer treatment proceeds, and the heart is protected alongside it rather than after it.

The Mechanism

Three treatment categories account for most of the cardiac concern in breast cancer, and each operates through a distinct biological mechanism that determines how the resulting injury presents, whether it is reversible, and how the monitoring and intervention approach should differ.

Anthracycline chemotherapy, which includes agents such as doxorubicin (Adriamycin) and epirubicin, causes cardiac injury primarily through oxidative stress and mitochondrial damage in cardiomyocytes. Reactive oxygen species generated during anthracycline metabolism damage the mitochondrial membrane, impair energy production in cardiac muscle cells, and ultimately lead to cardiomyocyte death. Because cardiomyocytes have very limited regenerative capacity, this cell loss is cumulative and largely irreversible, distinguishing anthracycline toxicity from other forms of drug-induced cardiac injury. The injury accumulates in a dose-dependent manner across treatment cycles. At lower cumulative doses the risk is real but modest; at higher cumulative doses, the risk of overt cardiomyopathy climbs steeply.

The 2016 European Society of Cardiology (ESC) cardio-oncology position paper quantified this relationship: overt cardiomyopathy occurs in roughly 5 percent of patients at standard cumulative doxorubicin doses around 300 mg/m2, rising to over 18 percent at 700 mg/m2. Even subclinical reductions in left ventricular ejection fraction (LVEF) appear more frequently at doses well below those thresholds and can progress if undetected, particularly in the presence of other cardiovascular risk factors. Importantly, subclinical LVEF decline during treatment predicts later symptomatic cardiomyopathy, which is why monitoring during therapy is intended to catch the decline early, not to wait for symptoms to develop.

HER2-targeted therapies, particularly trastuzumab (Herceptin) and pertuzumab, operate through a fundamentally different mechanism. Rather than direct cell death, they interfere with HER2 signaling pathways that cardiac cells rely on for stress recovery and maintenance. HER2 is expressed on cardiomyocytes and is part of a neuregulin signaling axis that supports myocardial repair after injury. Blocking this pathway does not cause cardiomyocyte death directly but leaves the heart less able to recover from concurrent stressors. The resulting cardiac dysfunction is classified as Type II cardiotoxicity in contrast to anthracycline Type I: generally not dose-dependent, not associated with ultrastructural damage on biopsy, and often reversible when treatment is paused and the heart is supported. A pooled analysis from pivotal HER2-targeted trials reported symptomatic heart failure in roughly 1 to 4 percent of patients receiving trastuzumab alone, rising to approximately 27 percent in older combination studies where trastuzumab was added concurrently to anthracyclines. The clinical implication of this interaction is that sequential use, anthracyclines first and trastuzumab after, is generally safer than concurrent use, though the sequencing depends on each patient’s cancer biology and oncologist’s judgment.

Chest radiation represents the third mechanism and operates on the longest timeline of the three. Radiation damages the coronary endothelium directly, promoting inflammation and accelerating atherosclerosis in the irradiated vessels. It also causes fibrosis of the pericardium and myocardium over time, and can affect the heart valves, particularly the aortic valve, in patients who received radiation to the mediastinum. The landmark 2013 Darby et al. study in the New England Journal of Medicine analyzed cardiac outcomes in 2,168 women who received radiotherapy for breast cancer in Sweden and Denmark between 1958 and 2001. The study found that the rate of major coronary events increased by 7.4 percent per gray of mean cardiac dose received, with no apparent lower threshold below which radiation had no cardiac effect. Left-sided breast tumors receive higher cardiac radiation doses by anatomy, placing left-sided breast cancer radiation as the higher-risk exposure, though modern radiation planning techniques that minimize cardiac dose have substantially reduced this risk compared to older techniques used in the historical datasets.

Cardiac effects of radiation can emerge years to decades after treatment completion. The latency before coronary events become clinically apparent is typically five to ten years for higher-dose exposures, with valvular and pericardial complications sometimes appearing even later. This extended timeline means that cardiovascular follow-up for women who received chest radiation cannot be a single post-treatment check; it must be a longitudinal program that extends across the survivorship period.

What the Evidence Shows

The cardio-oncology monitoring framework from ASCO and the ESC, most recently updated in 2022, moved the field from reactive to anticipatory. Rather than waiting for cardiac events to occur and then treating them, the framework recommends baseline cardiovascular risk assessment before initiating cardiotoxic therapy, stratifying patients into low, medium, high, or very high cardiac risk based on the planned treatment type, anticipated cumulative dose, prior cardiac history, and baseline cardiovascular risk factors. That risk stratification determines how intensively the heart is monitored and whether prophylactic cardioprotective interventions should be added before or during treatment.

The MANTICORE trial (2017, published in the Journal of Clinical Oncology, Pituskin et al.) was the first randomized trial to evaluate whether cardioprotective medication could prevent LVEF decline during trastuzumab-based treatment for HER2-positive breast cancer. The trial enrolled 94 patients randomized to bisoprolol, perindopril, or placebo alongside trastuzumab. Bisoprolol significantly reduced LVEF decline compared to placebo over the 12-month treatment period, with the primary endpoint (prevention of LVEF reduction of 10 percentage points or more from baseline) met in the bisoprolol group but not in the perindopril group. The trial was not large enough to define a universal prevention protocol and did not evaluate clinical cardiac events (which were too rare in this size trial), but it established the proof of concept that a beta-blocker added prophylactically during HER2-targeted therapy can limit asymptomatic cardiac dysfunction.

For anthracyclines, the agent with the strongest cardioprotective evidence is dexrazoxane, an iron-chelating compound that interferes with anthracycline-induced free radical generation in cardiac tissue. A meta-analysis in Annals of Oncology (2016, van Dalen et al.) pooled results from eight randomized trials and found that dexrazoxane significantly reduced the risk of clinical heart failure, with a relative risk of 0.29 (95% CI 0.20 to 0.41), without reducing tumor response rates. Historical concerns about whether dexrazoxane increased the risk of secondary malignancies have been substantially revised by subsequent analyses, including a 2014 systematic review that found no significant increase in second malignancy risk, though some caution persists in certain pediatric oncology protocols. In adults receiving high cumulative anthracycline doses, the cardioprotective benefit is well-documented and the risk-benefit calculation is generally favorable.

Survivorship data make the case that cardiac surveillance after cancer treatment is not optional. A 2019 analysis by Mehta et al., published in the Journal of the American College of Cardiology, used SEER-Medicare linked data to examine outcomes in more than 10,000 women aged 66 and older with stage I-III breast cancer. The analysis found that among survivors who lived beyond five years, cardiovascular disease was the leading cause of non-cancer death, and that among certain subgroups, particularly those with baseline cardiovascular risk factors and those who received anthracyclines, cardiovascular mortality exceeded breast cancer mortality at the 10-year follow-up mark. This finding quantifies what clinicians in cardio-oncology have recognized for years: for many breast cancer survivors, what threatens their life after the cancer is behind them is cardiovascular disease, not recurrence.

A 2018 analysis from the Danish Breast Cancer Cooperative Group (Krul et al., published in European Heart Journal) followed more than 20,000 women with breast cancer for a median of 8.9 years and found that breast cancer survivors had a 26 percent higher rate of heart failure compared to age-matched women without breast cancer, with the excess driven predominantly by anthracycline exposure. The hazard ratio for heart failure in women who received anthracyclines was 2.0 compared to women who did not, an excess risk that persisted even after adjusting for baseline cardiovascular risk factors.

Global Longitudinal Strain: Detecting Cardiotoxicity Before Left Ventricular Ejection Fraction Declines

Left ventricular ejection fraction is the standard cardiac monitoring metric in cardio-oncology, but it has a structural limitation: it can appear normal until a meaningful fraction of myocardial contractile function has already been lost. A patient’s LVEF can be 57 percent, within the normal range, while underlying subclinical myocardial injury from anthracycline exposure is already progressing. By the time LVEF falls below 53 percent, or drops by more than ten percentage points from baseline, the threshold that triggers a cardiotoxicity alert in most monitoring protocols, substantial cardiomyocyte loss may have already occurred.

Global longitudinal strain, measured by speckle-tracking echocardiography, offers earlier detection because it measures myocardial deformation rather than cavity size. GLS quantifies the percentage shortening of the myocardium along its longitudinal axis during systole. Normal GLS is approximately -20 percent, with more negative values indicating better contractile function. Subclinical myocardial injury from cardiotoxic chemotherapy characteristically reduces GLS before LVEF falls, because the myocardium contracts less efficiently before it remodels enough to reduce the ejection fraction measurably.

Thavendiranathan and colleagues published a validation study in the Journal of the American College of Cardiology in 2014, evaluating GLS reproducibility and sensitivity for detecting early cardiotoxicity in patients undergoing breast cancer treatment. GLS showed superior test-retest reproducibility compared with LVEF and detected subclinical contractile dysfunction in patients whose LVEF remained within normal range, establishing it as an earlier and more sensitive signal for myocardial injury. The American Society of Echocardiography and European Association of Cardiovascular Imaging 2014 consensus identified a relative GLS reduction of 15 percent or more from baseline, regardless of absolute LVEF value, as an early cardiotoxicity marker warranting clinical attention. 4 / Promising

The 2022 ESC cardio-oncology guidelines incorporated GLS as a standard component of cardiac monitoring during cardiotoxic therapy, recommending baseline GLS measurement before treatment initiation in patients at medium cardiac risk or above, followed by serial measurement at defined intervals. For women receiving anthracyclines, where the injury is cumulative and irreversible at the cardiomyocyte level, detecting a GLS decline before LVEF crosses the alert threshold provides additional time to consider dose modification, introduce cardioprotective medication, or accelerate monitoring frequency before cell loss becomes clinically significant.

The practical implication is specific: a woman undergoing anthracycline or trastuzumab treatment should ask not only whether an echocardiogram has been ordered, but whether GLS measurement is included in the monitoring protocol alongside LVEF. Standard echocardiogram reports do not always include GLS unless speckle-tracking software is applied and the measurement is specifically requested. A cardiac monitoring protocol limited to LVEF is less sensitive than one incorporating GLS, and the difference between waiting for LVEF to fall and catching a GLS decline early is the difference between reactive and anticipatory cardiac protection.

What to Do This Week

1. If you are currently undergoing or planning breast cancer treatment, ask your oncologist whether your regimen includes anthracyclines, HER2-targeted therapy, or chest radiation. For each that applies, ask specifically what the cardiac monitoring plan is and whether a baseline echocardiogram has been ordered or is indicated before the first dose.

2. If you are a breast cancer survivor, locate your treatment summary and confirm that it documents the specific agents used, cumulative doses (particularly cumulative anthracycline dose in mg/m2), and if applicable, the radiation field and mean cardiac dose received. If that documentation does not exist in your current medical record, request it from the treating oncology center.

3. Bring your cancer treatment history to your primary care clinician or cardiologist explicitly, not as background context but as a specific cardiac risk exposure that should be documented in your cardiovascular problem list and tracked. A woman who received doxorubicin 10 years ago needs that documented in her cardiovascular record and considered in any future cardiac evaluation.

4. Manage standard cardiovascular risk factors with particular attention: blood pressure, LDL cholesterol, blood glucose, smoking status, and physical activity. These risk factors compound the cardiac effects of anthracyclines and radiation, and optimizing them reduces the compounded risk. They are not a separate concern from cardio-oncology follow-up; they are a core part of it.

5. If you develop new breathlessness, a decline in exercise tolerance, ankle swelling, or palpitations in the months or years following cardiotoxic treatment, report it to your clinician in the explicit context of that treatment history. These symptoms should prompt cardiac evaluation that includes the treatment exposure as part of the assessment, not a general evaluation that treats you as a cardiac patient with no relevant history.

Breast cancer survival rates have improved dramatically, and the cardiac consequences of treatment are now predictable and manageable enough that they should not cause anyone to avoid effective therapy. The goal of cardio-oncology is not to make treatment safer by making it less effective; it is to protect the heart throughout and after cancer treatment so that women who survive breast cancer do not later lose years to heart disease that was preventable. Anticipating the risk before treatment, monitoring through therapy and after it, and folding cardiovascular care explicitly into the survivorship plan is how both the cancer and the heart get protected, rather than one outcome traded for the other.